KR101966374B1 - Composition for accelerating wound healing comprising and Aquilaria crassna extract and β-Glucan - Google Patents

Abstract

The present invention relates to a composition for accelerating wound healing containing an Aquilaria agallocha extract and β-glucan. More specifically, the present invention relates to the composition for accelerating wound healing, which is effective for skin damage, skin ulceration or wound healing by inducing regeneration of damaged skin in vivo.

Description

[0001] The present invention relates to a composition for accelerating wound healing, which comprises an acicular extract and beta-glucan,

The present invention relates to a composition for accelerating wound healing comprising an oxidized extract and beta-glucan, and more particularly to a composition for stimulating wound healing in vivo, which is effective for skin damage, skin ulceration or wound healing And to compositions for promoting wound healing.

Skin is the primary organ that protects or defends the body, but it is the largest organ covering the entire body surface, consisting of epidermis, dermis and subcutaneous tissue. The stratum corneum, which is located on the outermost layer of the epidermis, is composed of keratin and lipid while inhibiting the infiltration of harmful substances and evaporation of water and protecting the body from bacteria or external stimuli.

However, these skin surfaces are constantly damaged by external harmful environments such as ultraviolet rays, dry weather, cold winds, and incorrect washing habits. Because of this, the outermost part of the skin, which is the outer part of the skin, is constantly peeled off and the other cells that grow beneath it continue to take its place.

On the other hand, wound healing is a process of restoring damaged skin or tissue to a normal state. It is divided into three phases: inflammatory phase, proliferative phase, and remodeling phase (Doaa Mohamed Hasan et al. The Effect of Tamoxifen on Healing of Skin Wounds in Senile, Adult Ovariectomized and Adult Nonovariectomized Female Rats).

The inflammatory phase is the stage where the blood coagulates and the hemostasis occurs, and the wound is cleaned. The proliferative phase is a stage in which new blood vessel formation and collagen production occur and granulation tissue is formed. The remodeling phase is the final stage of wound healing, with proliferating epithelial cells maturing, fibrous tissue formation, angiogenesis, re-epithelialization, and extracellular matrix synthesis. Thus, wound healing involves various functions such as anti-inflammation, epithelial cell proliferation, and collagen synthesis.

One of the typical materials that regulate the wound healing process is growth factors, which control the growth, differentiation, and metabolism of cells throughout the wound healing process and regulate the surrounding environment. Among growth factors, epidermal growth factor (EGF) is an important growth factor in wound healing.

EGF has been reported to promote wound healing in skin, cornea, and mucosa through various studies. In addition, it has been known that EGF is externally applied to chronic wounds such as a tissue transplantation site and a diabetic foot stalk to facilitate epithelialization, thereby shortening the wound restoration rate (Barrientos S. et al., Growth factors and cytokines in Wound Repair Regen 2008 16 (5): 585-601). In addition, when the epidermal growth factor receptor is activated, it induces the production of growth factors such as VEGF and HGF, promotes the growth of keratinocytes and fibroblasts, and induces the production of collagen-like extracellular matrix in fibroblasts. For example, there is TGF-beta (transforming growth factor-beta). TGF-beta is a substance involved in growth and differentiation of various cells, and is a substance which regulates growth, regulates immune response, stimulates bone formation, induces cartilage-specific macromolecule, (Bennett, NT et al., Am. J. Surg. 165: 728, 1993).

However, most of the cosmetics or medicines for skin regeneration and wound healing developed until now contain a large amount of artificially produced compound components, resulting in side effects that are irritating to the skin or limit the ability to regenerate the skin. Therefore, recently, studies have been conducted to develop natural products which are free from side effects and which are inexpensive, and to treat wounds.

Accordingly, Korean Patent Registration No. 10-1372789 discloses a skin external composition composition and a functional food containing a rose terracotta tissue culture or an extract thereof, as disclosed in Korean Patent Laid-Open Publication No. 2016-0121847 There is known a cosmetic composition for skin regeneration and a pharmaceutical composition for treating wounds containing cinnamic acid or a white rice extract containing the same as an indicator component of white rice extract.

However, in the above-mentioned prior arts described above, the skin layer of the skin is simply improved to promote the skin wound treatment and regenerating effect, but no description has been made on the promotion of skin wound treatment through permeation into the dermal layer of the skin.

Korean Patent Publication No. 10-1372789 Korean Patent Publication No. 2016-0121847

In solving the above-mentioned problems, an object of the present invention is to provide a composition for accelerating wound healing, which comprises an oxidized extract and beta-glucan, which induces recovery of dermis in the skin and exhibits excellent wound healing effects.

It is another object of the present invention to provide a composition for accelerating wound healing, which can be used at low cost and stably including wounded extract as a natural product.

The present invention provides a composition for stimulating wound healing, which comprises an oxidized extract, beta-glucan and EGF protein according to an embodiment of the present invention as an active ingredient.

In one embodiment of the invention, the beta glucan is selected from the group consisting of beta- (1,3) -glucan, beta- (1,4) -glucan, beta- (1,6) Or mixtures thereof.

In addition, the beta-glucan may include beta- (1,6) glucan having a side chain in beta - (1,3).

The beta-glucan may have a molecular weight of 30,000 to 300,000 Da.

The beta-glucan may be derived from mycelia of Grifola frondosa.

The water-soluble extract may contain 0.0001 to 20% by weight of the total composition.

The EGF protein may be contained in an amount of 0.0001 to 0.001% by weight based on the total composition.

The beta-glucan may be contained in an amount of 0.001 to 9% by weight based on the total composition.

The composition may penetrate to the dermal layer of the skin to induce skin regeneration.

The compositions may be used as cosmetics or as skin and tissue fillers, wound epithelial replication or drug delivery vehicles.

As described above, the composition for accelerating wound healing, which comprises the intumescent extract and beta-glucan according to the present invention, can induce dermal restoration in the skin and exhibit an excellent wound healing effect.

In addition, the composition for promoting wound healing according to the present invention can promote wound healing at a low cost and stably, including a natural extract.

FIG. 1 is a photograph showing the progress of treatment for 3 months with a composition for promoting wound healing according to an embodiment of the present invention in a lower ulcer (gangrenous scarlet fever) before treatment and after treatment.
FIG. 2 is a graph showing the cell survival rate of human dermal fibroblast treated with beta-glucan contained in a composition for accelerating wound healing according to an embodiment of the present invention.
FIG. 3 is a graph showing the amount of collagen gene expression measured by treating beta-glucan contained in the composition for promoting wound healing according to an embodiment of the present invention with human dermal fibroblasts at different concentrations.
4 is a graph showing the cell proliferation effect of A431 cells treated with the concentration of Example 1 and Comparative Example 1 by concentration.
FIG. 5 is a graph showing the degree of synthesis of type I collagen by treating A431 cells by concentration in Example 1 and Comparative Example 1; FIG.

The accompanying drawings in the present invention may be exaggerated for clarity, clarity, and descriptive convenience. In addition, since the following terms are defined in consideration of the functions of the present invention, they may vary depending on the intention or custom of the user or the operator, and therefore the definition of these terms should be based on the technical contents throughout this specification will be. On the contrary, the embodiments are merely illustrative of the constituent elements set forth in the claims of the present invention and do not limit the scope of the present invention, and the scope of the rights should be interpreted on the basis of technical ideas throughout the specification of the present invention .

The present invention relates to a composition for accelerating wound healing comprising an aerial extract, beta-glucan and EGF protein as an active ingredient, and more particularly to a composition for promoting wound healing which permeates the dermal layer of skin and induces regeneration of the skin Lt; / RTI >

Here, the beta-glucan has a form of a polymer in which a glucose monomer is linked by a glycosidic bond. Beta Glucan can be derived from natural plants. For example, beta-glucan can be derived from mushrooms, homo cell walls, cereals, and the like. However, the beta-glucan which can be used for preparing the composition for promoting wound healing of the present invention can be induced not only by natural plants but also by chemical synthesis and polymerization. As a preferred embodiment, beta-glucan can be extracted from a culture medium of Grifola frondosa mycelium having a relatively high content of beta-glucan and a relatively short period of mycelial cultivation, compared to other mushrooms.

The effect of beta-glucan on the immune system has already been reported (FEMS immunology and medical microbiology, 13 (1): 51-57; Vetvicka, V et al, (1996)). In Japan, beta-glucan has been marketed as an anticancer drug or functional food, and the US FDA has established safety standards for beta-glucan to certify its immunity-increasing effect and its stability. Betaglucan is also used as a raw material for cosmetics in the skin care industry to enhance viscoelasticity, moisturizing properties, biocompatibility, promoting collagen synthesis, skin regeneration and protection (Journal of Cosmetic Science, 27 (5): 292).

Betaglucan is classified as beta - (1,3) - glucan, beta - (1,4) - glucan and beta - (1,6) - glucan depending on the position where glucose monomers are connected. Beta-glucans that can be used in the present invention include beta-1,3-glucans, beta- (1,4) -glucan, beta- (1,6) -glucan or a mixture of at least two of these, (1,3) -glucan, beta - (1,4) - glucan and beta - (1,6) - glucan having this side chain. Particularly, it is preferable to use beta - (1,6) - glucan having a side chain in the beta - (1,3) of the beta - glucans. The beta-glucan is preferably prepared by fractionating beta-glucan having a molecular weight of 30,000 to 300,000 Da to improve viscosity, swelling property, and extrudability of a syringe.

If the molecular weight of the beta-glucan is less than 30,000 Da, the economic cost of recovering the low-molecular-weight beta-glucan is increased. If the molecular weight of the beta-glucan exceeds 300,000 Da, it may be difficult to permeate into the skin dermis.

In addition, by containing beta-glucan in the composition for promoting wound healing, the composition can be delivered not only to the epidermis of the skin but also to the dermal layer of the skin, thereby inducing dermal restoration in the skin and exhibiting skin regeneration effect. Thus, the composition for promoting wound healing can promote skin regeneration and exhibit wound healing and improvement effects.

The beta-glucan may be contained in an amount of 0.001 to 9% by weight based on the total composition. When the beta-glucan is contained in an amount of less than 0.1% by weight based on the total composition, the skin penetration effect of beta-glucan to the dermal layer of the skin And when the amount of the beta-glucan is more than 0.5% by weight based on the total composition, skin irritation may be caused, and the effect on wound healing or improvement may be deteriorated. As a preferable example, the amount of the beta-glucan is 0.005-5 wt%, more preferably 0.01-2 wt%, but not limited thereto.

On the other hand, the acne has been used for a long time as a medicinal material or a spice, and it has been used for calming, dryness, aeration, indigestion, anorexia, vomiting, bronchial asthma, premature ejaculation, Dehydration is a defense function in case of injury, bacterium or fungus penetration into tree of Aquilaria of Thymelaeaceae distributed in Southeast Asia such as India, Vietnam, Laos and China, Is deposited. The inhibitory effects on the central nervous system (Okugawa H. et al. 1993) and the subcutaneous effects (Kakino M. et. Al. 2010) have been reported as the pharmacological activities of the immune system. 2008), anti-cancer effect (Gunasekera SP et al. 1981), anti-inflammatory effect (Zhou MH et al. 2008) and antiallergic effect (Kim YC et al.

The composition for promoting wound healing according to the present invention can inhibit inflammation caused by external influx or secondary bacteria by including an extract from the outside, .

In addition, the above-mentioned intrusion extract may be contained in an amount of 0.0001 to 20% by weight with respect to the total composition, and when the above-mentioned intrusion extract is contained in an amount of less than 0.0001% by weight based on the total composition, If the above-mentioned intrusion extract contains more than 20% by weight based on the total composition, the effect on wound healing or improvement may be deteriorated by a substance other than the active ingredient contained in the aerated extract. A preferred example thereof is 0.0001 to 10% by weight, more preferably 0.0001 to 5.0% by weight, based on the whole composition of the above-mentioned ingress extract.

On the other hand, it has been reported that EGF protein promotes wound healing of skin, cornea, mucous membrane and the like through various studies as described above. However, since it does not penetrate to the dermal layer of the skin, the wound healing or improving effect is insufficient, and the EGF protein content is increased to enhance the wound healing effect. However, this has a problem that the economic cost is very high. Accordingly, the present invention provides a composition for accelerating wound healing, which comprises EGF protein in an amount of 0.0001 to 0.001% by weight based on the total composition, .

Here, when the EGF protein is contained in an amount less than 0.0001% by weight based on the total composition, a wound healing effect exhibited by the EGF protein can not be expressed. When the EGF protein is more than 0.001% by weight based on the total composition, There is a drawback that the manufacturing cost can be increased. As a preferred example, the EGF protein is 0.0001 to 0.008% by weight, more preferably 0.0001 to 0.0005% by weight, based on the total composition.

The composition for accelerating wound healing provided by the present invention contains all of the above-mentioned ingredients in a specific amount, thereby inducing skin regeneration, promoting wound healing or improvement, and securing wound healing effect safely without side effects.

In the case of using a composition for promoting wound healing that provides wound healing or improvement of the present invention as an external preparation for skin, there is no particular limitation on the formulation thereof. For example, a formulation for lotion, ointment, gel, cream, patch or spray Can be manufactured.

The composition for accelerating wound healing of the present invention may be used as a cosmetic product or as a skin and tissue filler, a wound epithelium or a drug delivery device.

The composition for accelerating wound healing of the present invention may be used alone or in combination, or may be used in combination with another pharmaceutical or cosmetic composition other than the present invention. In addition, the composition having excellent skin wrinkle treatment promoting effect according to the present invention can be used according to the usual use method, and the use frequency can be changed according to the skin condition of the user.

Hereinafter, preferred embodiments of the present invention will be described. However, the embodiments of the present invention can be modified into various other forms, and the scope of the present invention is not limited to the embodiments described below. Further, the embodiments of the present invention are provided to more fully explain the present invention to those skilled in the art.

Manufacturing example  1. Composition for accelerating wound healing

1) Preparation of beta-glucan

β- (1,3), (1,6) -Glucan (water-soluble β-glucan produced by mycelial fermentation of leaf mushroom) was used as the material of this experiment. A method for preparing beta-1,6-branched-beta-1,3-glucan from mycelia of Grifola frondosa is as follows.

The mushroom mycelium is inoculated in liquid medium at 3% (v / v). Liquid medium is glucose 3%, yeast extract 0.5%, peptone 0.1%, a potassium phosphate (K2HPO4) 0.05%, one of potassium phosphate (KH2PO4) 0.05%, magnesium sulfate (MgSO ₄ · 7H ₂ O) nutrient containing 0.01% And cultured for 5 days using a medium (adjusted to pH 5.5) at a culture temperature of 25, a revolution of 200 rpm, and aeration amount of 1.0 vvm.

After the completion of the culture, 3.0% of diatomaceous earth and 1.0% of activated carbon powder were added to the culture solution and the mixture was stirred to adsorb unnecessary components such as coloring matters and protein components, followed by filtration with a filter device to obtain a solution of beta-1,6-branched-beta-1,3- ≪ / RTI > The beta-1,6-branched-beta-1,3-glucan solution was re-filtered using a 0.22 mu m filter and then ethyl alcohol was added to precipitate beta-1,6-branched- beta-1,3- Respectively. The recovered beta-1,6-branched-beta-1,3-glucan was dried by hot air at 60 DEG C to volatilize the alcohol component and then lyophilized. The dried beta-1,6-branched-beta-1,3-glucan was pulverized with a pulverizer to prepare a powder sample.

2) Manufacture of the extract

After crushing Aquilaria crassna imported from Vietnam, 30L of purified water was added to 20g of the aged powder, and the high temperature and high pressure was extracted at 121 캜 and 1.2 atm for 30 minutes. Then, the mixture was filtered with a 0.22 mu m filter to remove insoluble matter, concentrated under reduced pressure and lyophilized to prepare a powder sample.

3) Composition for accelerating wound healing

As shown in Table 1, Example 1, which is a composition for accelerating wound healing, was prepared by mixing EGF protein, beta-glucan, and ethanol extract and mixing the rest with purified water. In addition, Comparative Example 1 was prepared with a composition containing only EGF protein.

ingredient Example  One
(Total 100ml) Comparative Example  One
(Total 100ml) Beta-1,6-branched-beta-1,3-glucan 0.5 g - Europium extract 0.0005 g - EGF 0.0001 g 0.0001 g Purified water up to 100ml up to 100ml

Here, the commercially available product (Caregen, Korea) was used as the EGF protein. Betaglucan was extracted from the mycelia of leaf mushroom as described above, and the edible extract was prepared as described above.

1st Experimental Example Ulcer ulcer  Check wound treatment effect

Patients with lower limb ulceration (gangrenous gonadosomiasis) were coated with 3 ml of the wound healing composition, Example 1, prepared according to Preparation Example 1, once every day for 3 months. Then, in order to confirm that the lower limb ulcer improved, photographs before and after the treatment were taken and shown in Fig.

As shown in Fig. 1, the wound-healing composition of the present invention showed that the wounds healed 80% or more and the ulcers were much improved.

Second Experimental Example  : Determination of survival rate of human dermal fibroblasts by beta-glucan concentration

Human dermal fibroblasts were suspended in Fibroblast basal medium (cc-381, Lonza, Walkersvile, MD, USA) to confirm the growth of human dermal fibroblasts (nHDFs; Lonza, Basel, Switzerland) ) In a 5% CO ₂ cell incubator using a medium containing FGM ^TM -2 singleQuots ^™ (hGFG, insulin, FBS and gentamicin / amphotericin-B; cc-4126, Walkersvile, MD, USA) Lt; / RTI >

3 x 10 ³ human dermal fibroblasts were dispensed into each well of a 96-well plate and cultured for 24 hours. Then, beta-glucan was treated for each concentration and cultured for 24 hours.

After incubation for 30 minutes to 1 hour at 37 ° C, the microplate reader system (SpectraMax® i3x Multi-Mode Detection Platform, Molecular Devices, Sunnyvale, Calif., USA) Absorbance at 450 nm. The reference absorbance was measured at 650 nm and the result was corrected. The results were expressed as means ± standard deviation from three independent experiments. At this time, P <0.05 was verified by Student's t-test, and the results were significant, and the results are shown in FIG.

The control group of the human dermal fibroblast survival rate experiment was cultured in a medium containing dimethyl sulfoxide (DMSO) as a vehicle.

As shown in FIG. 2, in the human dermal fibroblast treated with 1 to 5% of beta-glucan, the proliferation of the human dermal fibroblast was active and the survival rate of the cells was almost 100%. However, The survival rate was lowered. Thus, it was confirmed that the presence of beta-glucan in an amount of 10% or more can inhibit the survival of human dermal fibroblasts.

Third Experimental Example  : Assessment of Collagen Gene Expression by Beta Glucan Concentration

The level of expression of COL1A1 gene, a representative component of type 1 collagen, was measured by quantitative real-time PCR to determine the expression level of collagen gene expressed from beta-glucan human dermal fibroblasts (nHDFs; Lonza, Basel, Switzerland) time PCR (qRT-PCR) assay.

Human dermal fibroblasts were transfected into Fibroblast basal medium (cc-381, Lonza, Walkersvile, MD, USA) with FGM ^™ -2 singleQuots ^™ (hGFG, insulin, FBS and gentamicin / amphotericin-B; cc-4126, Walkersvile, MD , USA) in a 5% CO ₂ cell incubator at 37 ° C.

1 x 10 &lt; ⁵ &gt; human dermal fibroblasts were dispensed into each well of a 6-well dish and cultured for 24 hours, followed by beta-glucan treatment for each concentration. After harvesting the cultured cells, cell lysis and total mRNA extraction were performed by adding 1 ml TRIzol reagent (Life Technologies). Total mRNA concentration and purity (A260 / A280 and A260 / A320 ratio) were verified using a MaestroNano® microvolume spectrophotometer (Maestrogen, Las Vegas, NV, USA) and only total mRNA with a purity of 2.0 or higher was selected. Total mRNA was replaced with cDNA using M-MLV reverse transcriptase (Life Technologies) and used for qRT-PCR. qRT-PCR was performed using HOT FIREPOL Evagreen PCR Mix Plus (Solis BioDyne, Estonia) and expression of the gene was analyzed using StepOnePlus ^TM Systems software (Applied Biosystems, USA). As a control for evaluation of the amount of collagen gene expression, a medium in which nothing was treated was used.

The PCR reaction conditions were denaturation at 94 ° C for 15 minutes, denaturation at 94 ° C for 30 seconds, annealing at 60 ° C for 30 seconds, and polymerization at 72 ° C for 30 seconds. Changes in gene expression were measured relative to the amount of β-ACTIN control gene expression. The C _T value of the COL1A1 was normalized (normalization) to the C _T values of the β-ACTIN, the relative expression of COL1A1 was calculated over the 2 ^-CT method. The results were expressed as means ± standard deviation from three independent experiments. At this time, P <0.05 was verified by Student's t-test, and the results were significant, and the results are shown in FIG. The primer sequence information used in the qRT-PCR test is shown in Table 2 below.

division Forward primers Reverse primers COL1A1 5'-AGGGCCAAGACGAAGACATC-3 ' 5'-AGATCACGTCATCGCACAACA-3 ' β-ACTIN 5'-GGATTCCTATGTGGGCGACGA-3 ' 5'-CGCTCGGTGAGGATCTTCATG-3 '

As shown in FIG. 3, the amount of COL1A1 mRNA expression was increased in a concentration-dependent manner as a result of measuring the amount of mRNA expression of COL1A1, a representative gene of Type 1 collagen against beta-glucan. In particular, treatment with beta-glucan at 5% concentration showed an increase in mRNA expression of COL1A1 by 70.62 ± 16.57% compared to the control group. Accordingly, it was confirmed that beta-glucan contained in the composition for promoting wound healing according to the present invention can promote collagen production by increasing collagen gene expression in human dermal fibroblasts.

Fourth Experimental Example  : By concentration of composition for promoting wound healing Assessment of cell proliferation

First, A431 cells were cultured in Dulbecco's modified Eagle's minimal medium supplemented with 10% fetal bovine serum (FBS, WelGENE Inc., Korea) and 100 units / ml penicillin / streptomycin (WelGENE Inc., Korea) ) Were cultured at 37 ° C in 5% CO ₂ .

The A431 cell culture 1 × 10 ³ / and by 250㎕ dispensed into 48well then cultured for 24 hours in CO ₂ incubator and diluted to the above Example 1 and Comparative Example 1 to 0.1 times and 0.3 times the percentage of each were treated in 2.5㎕ , Three times for two days, for a total of six days. 250 μl of MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide, Duchefa, Netherlands) was added to each well and incubated at 37 ° C for 3 to 4 hours The supernatant was removed and the generated formazan was dissolved in 250 μl of DMSO (Junsei, Japan). 100 μl of the solution was transferred to a 96-well plate and absorbance was measured at 570 nm using a microplate reader (Molecular Devices, Toronto, Canada).

The cell proliferation effect was determined from the following equation, and the results are shown in Fig.

[Cell proliferation effect calculation formula]

Cell proliferation effect (%) = (sample treated group absorbance - sample treated group absorbance) / control absorbance X 100

As shown in FIG. 4, Example 1 promoted the proliferation of A431 cells, and the cell proliferation promoting effect was excellent even at low concentrations. On the other hand, in Comparative Example 1, as the concentration was increased, the cell proliferation effect was lowered. Thus, it was confirmed that the cell proliferation effect of Example 1 containing beta-1,6-branched-beta-1,3-glucan and the ethanol extract was excellent, and that the composition for promoting wound healing of the present invention exhibited cell proliferation Not only showed the effect but also cytotoxicity at higher concentrations and promoted cell proliferation.

Fifth Experimental Example  : Type I collagen composition for promoting wound healing Evaluation of synthesis

After measuring the cell proliferation effect of the fourth experimental example, the amount of procollagen type I-peptide (PICP, Type-I C-peptide) was measured using a kit (Kit, Takara, Japan) using the supernatant of the remaining sample The degree of collagen synthesis in Example 1 and Comparative Example 1 was measured.

First, 100 占 퐇 of Antibody-POD confugate solution was added to a 96-well plate, and 20 占 퐇 of a cell supernatant prepared in Example 1 and Comparative Example 1 was added to each well. This was reacted for 3 hours at 37 ° C and then washed 4 times with 300 μl of PBS containing 1% Tween-20 (BioSesang, Korea). Substrate soluton (TMBZ) (100 μl) was added and reacted at room temperature for 15 minutes. Then, 100 μl stop solution was added to stop the reaction and absorbance was measured at 450 nm with a microplate reader (Molecular Devices, Toronto, Canada). The results are shown in Fig.

As can be seen from FIG. 5, the amount of type I procollagen was increased by Example 1. Accordingly, the composition for accelerating wound healing of the present invention contains betaglucan, an aqueous extract, and EGF protein, thereby promoting the expression of extracellular matrix proteins such as type I collagen in keratinocytes, thereby effectively healing skin wounds Respectively.

Accordingly, the composition for promoting wound healing according to the present invention can be effectively used for promoting skin wounds by inducing collagen synthesis and cell regeneration of the skin, particularly when applied to damaged skin, skin ulcer or scarred skin.

As described above, the present invention has been described with reference to the embodiments shown in the drawings. However, it should be understood that the present invention is by way of example only and that various modifications and equivalent embodiments are possible on the basis of common knowledge in the art . Therefore, the true technical protection scope of the present invention should be determined based on the detailed contents of the above-mentioned invention in accordance with the claims to be described below.

Claims (9)

(EGF) protein as an active ingredient,
Wherein said beta-glucan is contained in an amount of 0.001 to 9% by weight based on the total composition,
Wherein said beta-glucan is beta-1,6-branched-beta-1,3-glucan prepared from mycelia of Grifola frondosa. delete delete The method according to claim 1,
Wherein the beta-glucan has a molecular weight of 30,000 to 300,000 Da. The method according to claim 1,
The composition for accelerating wound healing according to any one of claims 1 to 3, wherein the water-soluble extract comprises 0.0001 to 20% by weight of the total composition. The method according to claim 1,
Wherein the EGF protein is contained in an amount of 0.0001 to 0.001% by weight based on the total composition. delete The method according to claim 1,
Wherein the composition penetrates to the dermal layer of the skin to induce skin regeneration. The method according to claim 1,
Wherein the composition is used as a cosmetic product or as a skin and tissue filler, a wound epithelium replica or a drug delivery device.

Images